boehringer ingelheim glp-1 ADA: Tolerability questions linger for Boehringer's obesity drug GLP 1 Receptor Agonist Cardiovascular
Description
Whilst emerging evidence suggests potential mood benefits, GLP-1 agonists are not without adverse effects, and mental health monitoring remains important during treatment
Obesity is a complex condition extending beyond metabolic complications and has been shown to lead to neurologic disorders
UnitedHealthcare approval varies by specific plan and medical documentation quality
Future direction and relevance for gut-brain interventions More broadly, our review on the modulatory role of ghrelin and GLP-1 in reward processing adds to the growing evidence on the potential of gut-based interventions for motivational and emotional dysfunctions across a range of mental and metabolic disorders (Cryan et al., 2019
It should not be read as medical advice, a treatment recommendation, or a guarantee that any prescription will be issued
